297 related articles for article (PubMed ID: 30477526)
1. Long-term virological outcome in children receiving first-line antiretroviral therapy.
Chandrasekaran P; Shet A; Srinivasan R; Sanjeeva GN; Subramanyan S; Sunderesan S; Ramesh K; Gopalan B; Suresh E; Poornagangadevi N; Hanna LE; Chandrasekar C; Wanke C; Swaminathan S
AIDS Res Ther; 2018 Nov; 15(1):23. PubMed ID: 30477526
[TBL] [Abstract][Full Text] [Related]
2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
3. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
6. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
7. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
8. Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.
Rath BA; von Kleist M; Castillo ME; Kolevic L; Caballero P; Soto-Castellares G; Amedee AM; Robinson JE; Katzenstein DK; Van Dyke RB; Oberhelman RA
BMC Infect Dis; 2013 Jan; 13():1. PubMed ID: 23280237
[TBL] [Abstract][Full Text] [Related]
9. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana.
Barry O; Powell J; Renner L; Bonney EY; Prin M; Ampofo W; Kusah J; Goka B; Sagoe KW; Shabanova V; Paintsil E
BMC Infect Dis; 2013 Oct; 13():476. PubMed ID: 24119088
[TBL] [Abstract][Full Text] [Related]
11. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.
Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G
BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277
[TBL] [Abstract][Full Text] [Related]
12. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
[TBL] [Abstract][Full Text] [Related]
13. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.
Fairlie L; Karalius B; Patel K; van Dyke RB; Hazra R; Hernán MA; Siberry GK; Seage GR; Agwu A; Wiznia A;
AIDS; 2015 Oct; 29(16):2109-19. PubMed ID: 26182197
[TBL] [Abstract][Full Text] [Related]
14. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
18. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Ndembi N; Murtala-Ibrahim F; Tola M; Jumare J; Aliyu A; Alabi P; Mensah C; Abimiku A; Quiñones-Mateu ME; Crowell TA; Rhee SY; Shafer RW; Gupta R; Blattner W; Charurat ME; Dakum P
AIDS Res Ther; 2020 Nov; 17(1):64. PubMed ID: 33143751
[TBL] [Abstract][Full Text] [Related]
19. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire.
Adjé-Touré C; Hanson DL; Talla-Nzussouo N; Borget MY; Kouadio LY; Tossou O; Fassinou P; Bissagnene E; Kadio A; Nolan ML; Nkengasong JN
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):911-7. PubMed ID: 18593341
[TBL] [Abstract][Full Text] [Related]
20. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
